摘要
目的:观察应用麝香保心丸辅助治疗慢性心力衰竭(Chronic Heart Failure,CHF)的临床治疗效果及其对患者生物学标志物的影响。方法:将120例冠状动脉粥样硬化性心脏病(简称冠心病)合并CHF患者分为两组,其中保心丸组60例,在应用常规治疗CHF的基础上加用麝香保心丸;常规组60例,接受常规CHF药物治疗。分别对两组患者进行3个月的随访,对比两组临床有效率、中医证候评分水平,比较两组患者治疗前后左室射血分数(Left Ventricular Ejection Fraction,LVEF)、生物学标志物:N末端脑钠肽前体(N-terminal pro-brain Natriuretic Peptide,NT-proBNP)、可溶性ST2(Soluble ST2,sST2)、内皮素-1(Endothelin-1,ET-1)、一氧化氮(Nitric Oxide,NO)水平的变化情况。结果:与治疗前相比较,两组患者治疗后症状改善,保心丸组的临床有效率高于常规组,中医证候评分低于常规组;两组患者治疗后LVEF、NO较治疗前升高,NT-proBNP、sST2、ET-1较治疗前降低(P<0.05),且保心丸组改善程度显著优于常规组(P<0.05)。结论:麝香保心丸用于CHF的辅助治疗,可以抑制心肌重构,进一步改善患者心功能,更好地改善生物学标志物指标。
Objective:To observe the clinical efficacy of Shexiang Baoxin Wan(麝香保心丸)on biomarkers of patients with chronic heart failure.Methods:120 cases divided into two group.All patients treated with routine medication for heart failure.60 patients in the Baoxin Wan group additionally took Shexiang Baoxin Wan.Results:Compared with before treatment,the symptoms and TCM symptoms score improved after treatment,the levels of NT-proBNP,sST2,ET-1 in the two groups were lower than those before treatment,and LVEF,NO were higher than those before treatment(P<0.05);and the improvement degree in the Baoxin Wan group was significantly better than the control group(P<0.05).Conclusion:Shexiang Baoxin Wan on chronic heart failure can inhibit myocardial remodeling,improve cardiac function and biomarkers.
出处
《中医临床研究》
2021年第20期47-50,共4页
Clinical Journal Of Chinese Medicine
